Intellectual Property

AccenGen has identified different sEH inhibitor technologies developed at prominent East Coast and West Coast Universities and intends to develop its products based on the sEH platform. AccenGen realizes that these different technologies provide it access to a broad range of sEH inhibitor compounds that may be therapeutically efficacious for a wide variety of indications. AccenGen is poised to develop and commercialize those compounds that it believes to be best-in-class for a particular indication and that are deemed to have the best return on investment and over a relatively short period of time. As the use of sEH compounds is rapidly being recognized in the pharmaceutical, medical and other scientific communities, AccenGen will soon be uniquely positioned to establish therapeutic values of certain sEH compounds for other indications stemming from the same platform as well. AccenGen is well-situated to enjoy long-term sustained growth.